18 results on '"Dohan, A."'
Search Results
2. Preoperative Arterial Embolization of Musculoskeletal Tumors: A Tertiary Center Experience
- Author
-
Kedra, Alice, primary, Dohan, Anthony, additional, Biau, David, additional, Belbachir, Anissa, additional, Dautry, Raphael, additional, Lucas, Alexandre, additional, Aissaoui, Mathilde, additional, Feydy, Antoine, additional, Soyer, Philippe, additional, and Barat, Maxime, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Multiple Laparoscopic Liver Resection for Colorectal Liver Metastases
- Author
-
Nassar, Alexandra, primary, Tzedakis, Stylianos, additional, Dhote, Alix, additional, Strigalev, Marie, additional, Coriat, Romain, additional, Karoui, Mehdi, additional, Dohan, Anthony, additional, Gaillard, Martin, additional, Marchese, Ugo, additional, and Fuks, David, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
- Author
-
Mortier, Victor, primary, Wei, Felix, additional, Pellat, Anna, additional, Marchese, Ugo, additional, Dohan, Anthony, additional, Brezault, Catherine, additional, Barat, Maxime, additional, Fuks, David, additional, Soyer, Philippe, additional, and Coriat, Romain, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
- Author
-
Victor Mortier, Felix Wei, Anna Pellat, Ugo Marchese, Anthony Dohan, Catherine Brezault, Maxime Barat, David Fuks, Philippe Soyer, and Romain Coriat
- Subjects
pancreatic adenocarcinoma ,adjuvant chemotherapy ,FOLFIRINOX ,gemcitabine ,sarcopenia ,Cancer Research ,Oncology - Abstract
Background: Despite its toxicity, modified FOLFIRINOX is the main chemotherapy for localized, operable pancreatic adenocarcinomas. Sarcopenia is known as a factor in lower overall survival (OS). The purpose of this study was to assess the impact of sarcopenia on OS in patients with localized pancreatic ductal adenocarcinoma (PDAC) who received modified FOLFIRINOX or gemcitabine as adjuvant chemotherapy. Methods: Patients with operated PDAC who received gemcitabine-based (GEM group) or oxaliplatin-based (OXA group) adjuvant chemotherapy between 2008 and 2021 were retrospectively included. Sarcopenia was estimated on a baseline computed tomography (CT) examination using the skeletal muscular index (SMI). The primary evaluation criterion was OS. Secondary evaluation criteria were disease-free survival (DFS) and toxicity. Results: Seventy patients treated with gemcitabine-based (n = 49) and oxaliplatin-based (n = 21) chemotherapy were included, with a total of fifteen sarcopenic patients (eight in the GEM group and seven in the OXA group). The median OS was shorter in sarcopenic patients (25 months) compared to non-sarcopenic patients (158 months) (p = 0.01). A longer OS was observed in GEM non-sarcopenic patients (158 months) compared to OXA sarcopenic patients (14.4 months) (p < 0.01). The median OS was 157.7 months in the GEM group vs. 34.1 months in the OXA group (p = 0.13). No differences in median DFS were found between the GEM group and OXA group. More toxicity events were observed in the OXA group (50%) than in the GEM group (10%), including vomiting (p = 0.02), mucositis (p = 0.01) and neuropathy (p = 0.01). Conclusion: Sarcopenia is associated with a worse prognosis in patients with localized operated PDAC whatever the delivered adjuvant chemotherapy.
- Published
- 2022
6. Preoperative Arterial Embolization of Musculoskeletal Tumors: A Tertiary Center Experience
- Author
-
Alice Kedra, Anthony Dohan, David Biau, Anissa Belbachir, Raphael Dautry, Alexandre Lucas, Mathilde Aissaoui, Antoine Feydy, Philippe Soyer, and Maxime Barat
- Subjects
blood loss ,surgical ,bone neoplasms ,embolization ,preoperative ,musculoskeletal ,gelatin sponge ,microspheres ,Onyx ,Cancer Research ,Oncology - Abstract
The purpose of this study was to report the effectiveness of preoperative transcatheter arterial embolization (TAE) of musculoskeletal tumors in terms of blood loss and functional outcomes. Patients who underwent preoperative TAE of hypervascular musculoskeletal tumors between January 2018 and December 2021 were retrospectively included. The patients’ characteristics, TAE procedure details, degree of post-TAE devascularization, surgical outcomes in terms of red blood cell transfusion and functional results were collected. The degree of devascularization was compared between patients who had peri-operative transfusion and those who did not. Thirty-one patients were included. The 31 TAE procedures led to complete (58%) or near-complete (42%) tumor devascularization. Twenty-two patients (71%) had no blood transfusion during surgery. Nine patients (29%) had a blood transfusion, with a median number of red blood cell packs of three (q1, 2; q3, 4; range: 1–4). Eight patients (27%) had complete improvement of the initial musculoskeletal symptoms at the end of the follow-up, 15 (50%) had partially satisfying improvement, 4 (13%) had partially unsatisfying improvement and 3 (10%) had no improvement. Our study suggests that preoperative TAE of hypervascular musculoskeletal tumors allowed for bloodless surgery in 71% of patients and minimal transfusion needs for the remaining 29%.
- Published
- 2023
7. The Role of Magnetic Resonance Imaging in the Management of Esophageal Cancer
- Author
-
Pellat, Anna, primary, Dohan, Anthony, additional, Soyer, Philippe, additional, Veziant, Julie, additional, Coriat, Romain, additional, and Barret, Maximilien, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors
- Author
-
Ugo Marchese, Martin Gaillard, Anna Pellat, Stylianos Tzedakis, Einas Abou Ali, Anthony Dohan, Maxime Barat, Philippe Soyer, David Fuks, and Romain Coriat
- Subjects
Cancer Research ,Oncology ,pancreatic sparing surgery ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Review ,pancreatectomy ,chemotherapy ,therapeutic strategy ,pancreatic neuroendocrine tumor ,enucleation ,RC254-282 - Abstract
Simple Summary As we are facing an increasing incidence of pancreatic neuroendocrine tumors (pNETs), it appears necessary to better classify this disease—and in 2017 the WHO classification introduced a new category of well differentiated grade 3 tumors. pNETs treatment requires some specific background and recent reviews on the multimodal management of this disease are missing. Indeed, those modalities constantly evolve and this review, focusing on Grade 1 and Grade 2 pNETs, aims to clarify both oncological and surgical treatment options from localized tumors to multi metastatic disease. Every aspect of the strategy are discussed in this review from the oncologist and the surgeon’s point of view and with a special focus on a minimally invasive approach. Abstract Pancreatic neuroendocrine tumors (p-NETs) are rare tumors with a recent growing incidence. In the 2017 WHO classification, p-NETs are classified into well-differentiated (i.e., p-NETs grade 1 to 3) and poorly differentiated neuroendocrine carcinomas (i.e., p-NECs). P-NETs G1 and G2 are often non-functioning tumors, of which the prognosis depends on the metastatic status. In the localized setting, p-NETs should be surgically managed, as no benefit for adjuvant chemotherapy has been demonstrated. Parenchymal sparing resection, including both duodenum and pancreas, are safe procedures in selected patients with reduced endocrine and exocrine long-term dysfunction. When the p-NET is benign or borderline malignant, this surgical option is associated with low rates of severe postoperative morbidity and in-hospital mortality. This narrative review offers comments, tips, and tricks from reviewing the available literature on these different options in order to clarify their indications. We also sum up the overall current data on p-NETs G1 and G2 management.
- Published
- 2022
9. Multiple Laparoscopic Liver Resection for Colorectal Liver Metastases
- Author
-
Alexandra Nassar, Stylianos Tzedakis, Alix Dhote, Marie Strigalev, Romain Coriat, Mehdi Karoui, Anthony Dohan, Martin Gaillard, Ugo Marchese, and David Fuks
- Subjects
Cancer Research ,Oncology - Abstract
Over the past decades, liver cancer’s minimally invasive approach has primarily become as a new standard of oncological care. Colorectal liver metastases (CRLM) are one of the most developed indications of laparoscopic liver resection (LLR). CRLM resection is still the best treatment known in terms of survival. As multiple CRLM are found in up to 80% of cases at diagnosis (Manfredi S. and al, Annals of Surgery 2006), a lot of possible technical management approaches are described. With the development of the parenchymal-sparing strategy, multiple concomitant laparoscopic liver resections (LLR) are gaining acceptance. However, no recommendation is available regarding its indications and feasibility. Also, laparoscopic two-stage hepatectomy is developing for bilobar CRLM, and this also does not have established recommendation. The purpose of this paper was to highlight novelty and updates in the field of multiple minimally invasive liver resections. A review of the international literature was performed. The feasibility of laparoscopic concomitant multiple LLR and two-stage hepatectomy for CRLM as well as their outcomes were discussed. These clarifications could further guide the implementation of minimal resection in multiple colorectal liver metastases therapies.
- Published
- 2023
10. Adrenal Mass Characterization in the Era of Quantitative Imaging: State of the Art
- Author
-
Barat, Maxime, primary, Cottereau, Anne-Ségolène, additional, Gaujoux, Sébastien, additional, Tenenbaum, Florence, additional, Sibony, Mathilde, additional, Bertherat, Jérôme, additional, Libé, Rossella, additional, Gaillard, Martin, additional, Jouinot, Anne, additional, Assié, Guillaume, additional, Hoeffel, Christine, additional, Soyer, Philippe, additional, and Dohan, Anthony, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors
- Author
-
Marchese, Ugo, primary, Gaillard, Martin, additional, Pellat, Anna, additional, Tzedakis, Stylianos, additional, Abou Ali, Einas, additional, Dohan, Anthony, additional, Barat, Maxime, additional, Soyer, Philippe, additional, Fuks, David, additional, and Coriat, Romain, additional
- Published
- 2022
- Full Text
- View/download PDF
12. Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
- Author
-
Barat, Maxime, primary, Aldhaheri, Rauda, additional, Dohan, Anthony, additional, Fuks, David, additional, Kedra, Alice, additional, Hoeffel, Christine, additional, Oudjit, Ammar, additional, Coriat, Romain, additional, Barret, Maximilien, additional, Terris, Benoit, additional, Marchese, Ugo, additional, and Soyer, Philippe, additional
- Published
- 2021
- Full Text
- View/download PDF
13. The Role of Magnetic Resonance Imaging in the Management of Esophageal Cancer
- Author
-
Anna Pellat, Anthony Dohan, Philippe Soyer, Julie Veziant, Romain Coriat, and Maximilien Barret
- Subjects
Cancer Research ,Oncology - Abstract
Esophageal cancer (EC) is the eighth more frequent cancer worldwide, with a poor prognosis. Initial staging is critical to decide on the best individual treatment approach. Current modalities for the assessment of EC are irradiating techniques, such as computed tomography (CT) and positron emission tomography/CT, or invasive techniques, such as digestive endoscopy and endoscopic ultrasound. Magnetic resonance imaging (MRI) is a non-invasive and non-irradiating imaging technique that provides high degrees of soft tissue contrast, with good depiction of the esophageal wall and the esophagogastric junction. Various sequences of MRI have shown good performance in initial tumor and lymph node staging in EC. Diffusion-weighted MRI has also demonstrated capabilities in the evaluation of tumor response to chemoradiotherapy. To date, there is not enough data to consider whole body MRI as a routine investigation for the detection of initial metastases or for prediction of distant recurrence. This narrative review summarizes the current knowledge on MRI for the management of EC.
- Published
- 2022
14. Preoperative Detection of Liver Involvement by Right-Sided Adrenocortical Carcinoma Using CT and MRI
- Author
-
Kedra, Alice, primary, Dohan, Anthony, additional, Gaujoux, Sébastien, additional, Sibony, Mathilde, additional, Jouinot, Anne, additional, Assié, Guillaume, additional, Groussin Rouiller, Lionel, additional, Libé, Rossella, additional, Bertherat, Jérôme, additional, Soyer, Philippe, additional, and Barat, Maxime, additional
- Published
- 2021
- Full Text
- View/download PDF
15. Adrenal Mass Characterization in the Era of Quantitative Imaging: State of the Art
- Author
-
Maxime Barat, Anne-Ségolène Cottereau, Sébastien Gaujoux, Florence Tenenbaum, Mathilde Sibony, Jérôme Bertherat, Rossella Libé, Martin Gaillard, Anne Jouinot, Guillaume Assié, Christine Hoeffel, Philippe Soyer, and Anthony Dohan
- Subjects
adrenal glands ,Cancer Research ,Oncology ,adrenal gland disease ,adrenal glands neoplasm ,magnetic resonance imaging ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,X-rays computed ,tomography ,RC254-282 - Abstract
Detection and characterization of adrenal lesions have evolved during the past two decades. Although the role of imaging in adrenal lesions associated with hormonal secretion is usually straightforward, characterization of non-functioning adrenal lesions may be challenging to confidently identify those that need to be resected. Although many adrenal lesions can be readily diagnosed when they display typical imaging features, the diagnosis may be challenging for atypical lesions. Computed tomography (CT) remains the cornerstone of adrenal imaging, but other morphological or functional modalities can be used in combination to reach a diagnosis and avoid useless biopsy or surgery. Early- and delayed-phase contrast-enhanced CT images are essential for diagnosing lipid-poor adenoma. Ongoing studies are evaluating the capabilities of dual-energy CT to provide valid virtual non-contrast attenuation and iodine density measurements from contrast-enhanced examinations. Adrenal lesions with attenuation values between 10 and 30 Hounsfield units (HU) on unenhanced CT can be characterized by MRI when iodinated contrast material injection cannot be performed. 18F-FDG PET/CT helps differentiate between atypical benign and malignant adrenal lesions, with the adrenal-to-liver maximum standardized uptake value ratio being the most discriminative variable. Recent studies evaluating the capabilities of radiomics and artificial intelligence have shown encouraging results.
- Published
- 2022
16. Organ Preservation after Endoscopic Resection of Early Esophageal Cancer with a High Risk of Lymph Node Involvement
- Author
-
Dermine, Solène, primary, Lévi-Strauss, Thomas, additional, Abou Ali, Einas, additional, Belle, Arthur, additional, Leblanc, Sarah, additional, Bibault, Jean-Emmanuel, additional, Barré, Amélie, additional, Palmieri, Lola-Jade, additional, Brezault, Catherine, additional, Dhooge, Marion, additional, Terris, Benoit, additional, Dohan, Anthony, additional, Soyer, Philippe, additional, Berger, Arthur, additional, Rahmi, Gabriel, additional, Coriat, Romain, additional, Chaussade, Stanislas, additional, and Barret, Maximilien, additional
- Published
- 2020
- Full Text
- View/download PDF
17. Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
- Author
-
Philippe Soyer, Maxime Barat, Anthony Dohan, Christine Hoeffel, Ammar Oudjit, Alice Kedra, Rauda Aldhaheri, David Fuks, Benoit Terris, Maximilien Barret, Ugo Marchese, and Romain Coriat
- Subjects
Cancer Research ,medicine.medical_specialty ,carcinoma ,pancreatic ductal ,pancreatic neoplasms ,tomography ,X-ray computed ,Pancreatic ductal adenocarcinoma ,Computed tomography ,Gastroenterology ,Article ,030218 nuclear medicine & medical imaging ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Parenchyma ,medicine ,Carcinoma ,RC254-282 ,medicine.diagnostic_test ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Nomogram ,medicine.disease ,digestive system diseases ,Oncology ,030220 oncology & carcinogenesis ,Lymph ,business ,Arterial phase - Abstract
Simple Summary The purpose of this retrospective study was to report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and PDAC. At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29.93; p = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13–33.51; p = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.51–34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27–49.91) were independently associated with PPM. A nomogram based on CT features identified at multivariable analysis yielded an AUC of 0.92 (95% CI: 0.85–0.98) for the diagnosis of PPM vs. PDAC. Abstract Purpose: To report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and pancreatic ductal adenocarcinoma (PDAC). Materials and methods: Thirty-four patients (24 men, 12 women; mean age, 63.3 ± 10.2 [SD] years) with CT and histopathologically proven PPM were analyzed by two independent readers and compared to 34 patients with PDAC. Diagnosis performances of each variable for the diagnosis of PPM against PDAC were calculated. Univariable and multivariable analyses were performed. A nomogram was developed to diagnose PPM against PDAC. Results: PPM mostly presented as single (34/34; 100%), enhancing (34/34; 100%), solid (27/34; 79%) pancreatic lesion without visible associated lymph nodes (24/34; 71%) and no Wirsung duct enlargement (29/34; 85%). At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29.93; p = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13–33.51; p = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.512–34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27–49.91) were independently associated with PPM. The nomogram yielded an AUC of 0.92 (95% CI: 0.85–0.98) for the diagnosis of PPM vs. PDAC. Conclusion: CT findings may help discriminate between PPM and PDAC.
- Published
- 2021
18. Preoperative Detection of Liver Involvement by Right-Sided Adrenocortical Carcinoma Using CT and MRI
- Author
-
Guillaume Assié, Jérôme Bertherat, Sébastien Gaujoux, Lionel Groussin Rouiller, Anne Jouinot, Rossella Libé, Maxime Barat, Mathilde Sibony, Philippe Soyer, Anthony Dohan, and Alice Kedra
- Subjects
Cancer Research ,medicine.medical_treatment ,030209 endocrinology & metabolism ,liver ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,hepatectomy ,0302 clinical medicine ,adrenocortical carcinoma ,neoplasm ,staging ,Medicine ,Adrenocortical carcinoma ,In patient ,Receiver operating characteristic ,business.industry ,En bloc resection ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Oncology ,030220 oncology & carcinogenesis ,Hepatectomy ,business ,Nuclear medicine ,Kappa ,Preoperative imaging - Abstract
Simple Summary The major prognosis factor of adrenocortical carcinoma is the completeness of surgery. Focal adrenocortical carcinoma bulge on computed tomography and adrenocortical carcinoma contour disruption on magnetic resonance imaging are highly reproducible signs. These signs are strongly associated with direct liver involvement by right-sided adrenocortical carcinoma on preoperative imaging. These findings may help surgeons plan surgical approach before resection and decrease the complication rate. Abstract The major prognosis factor of adrenocortical carcinoma (ACC) is the completeness of surgery. The aim of our study was to identify preoperative imaging features associated with direct liver involvement (DLI) by right-sided ACC. Two radiologists, blinded to the outcome, independently reviewed preoperative CT and MRI examinations for eight signs of DLI, in patients operated for right-sided ACC and retrospectively included from November 2007 to January 2020. DLI was confirmed using surgical and histopathological findings. Kappa values were calculated. Univariable and multivariable analyses were performed by using a logistic regression model. Receiver operating characteristic (ROC) curves were built for CT and MRI. Twenty-nine patients were included. Seven patients had DLI requiring en bloc resection. At multivariable analysis, focal ACC bulge was the single independent sign associated with DLI on CT (OR: 60.00; 95% CI: 4.60–782.40; p < 0.001), and ACC contour disruption was the single independent sign associated with DLI on MRI (OR: 126.00; 95% CI: 6.82–2328.21; p < 0.001). Both signs were highly reproducible, with respective kappa values of 0.85 and 0.91. The areas under ROC curves of MRI and CT models were not different (p = 0.838). Focal ACC bulge on CT and ACC contour disruption on MRI are independent and highly reproducible signs, strongly associated with DLI by right-sided ACC on preoperative imaging. MRI does not improve the preoperative assessment of DLI by comparison with CT.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.